Nasdaq Files Form 25 to Remove Inozyme Pharma Shares from Listing

Rhea-AI Filing Summary

Inozyme Pharma, Inc. (INZY) has submitted a Form 25 to the SEC, signaling the removal of its common stock from listing and registration on the Nasdaq Stock Market under Section 12(b) of the Exchange Act.

The document, signed by Nasdaq AVP Tara Petta on 2025-07-01, states that the exchange has met all procedural requirements of Rule 12d2-2 for striking the security. The filing covers only the company’s common stock and does not disclose the reason for the delisting—whether involuntary (e.g., non-compliance) or voluntary (e.g., merger, alternate listing).

After effectiveness, trading in INZY shares on Nasdaq will cease and the Section 12(b) registration will be withdrawn 10 days later, materially affecting share liquidity, index eligibility, and disclosure obligations. Investors should watch subsequent SEC filings or company announcements for context on trading venue migration (such as OTC) and any strategic ramifications.

Positive

• None.

Negative

• Primary trading venue loss: Nasdaq delisting will sharply reduce liquidity and may force institutional exits.
• Unspecified rationale: Filing offers no explanation, generating uncertainty about compliance status or strategic direction.
• Potential index removal: Loss of Nasdaq listing can trigger exclusion from passive index funds, adding sell-side pressure.

Insights

Securities Analyst

TL;DR Delisting from Nasdaq removes primary trading venue, elevating liquidity and valuation risk.

The Form 25 confirms INZY will lose its Nasdaq quotation, a negative liquidity event that typically expands bid-ask spreads, limits institutional ownership, and can trigger index deletions. Without clarity on the cause—compliance failure versus corporate action—investors face uncertainty regarding future disclosure cadence and capital-raising ability. Near-term share price pressure is likely until alternative trading arrangements or strategic updates emerge.

Corporate Governance Expert

TL;DR Nasdaq certifies rule compliance; governance transparency now critical for stakeholders.

The exchange’s certification under Rule 12d2-2 suggests procedural completeness, yet the absence of rationale raises governance concerns. Voluntary withdrawals usually accompany detailed issuer communication; involuntary removals often signal regulatory breaches. The board should promptly explain the delisting’s context to preserve investor confidence and mitigate legal exposure related to disclosure duties.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-39397

Issuer:	Inozyme Pharma, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	321 Summer Street, Suite 400
	Boston	MASSACHUSETTS	02210
Telephone number:					857-856-5748

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-07-01	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Inozyme Pharma (INZY) file Form 25?

The filing removes INZY common stock from Nasdaq listing and Section 12(b) registration; no specific reason is provided in the document.

When will INZY shares stop trading on Nasdaq?

Trading typically ceases when Form 25 becomes effective; the document is dated 2025-07-01.

Will Inozyme Pharma still be an SEC-reporting company after delisting?

Section 12(b) registration is withdrawn, but INZY may remain subject to other reporting requirements unless it files to terminate them separately.

Where can investors trade INZY after the Nasdaq delisting?

The filing does not specify, but delisted shares often migrate to OTC markets; investors should monitor future company updates.